Ken Fisher
CYTK icon

Ken Fisher’s Cytokinetics CYTK Stock Holding History

Ken Fisher’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.4M Sell
743,697
-24,567
-3% -$1.76M 0.02% 220
2026
Q1 		$50.6M Sell
768,264
-54,621
-7% -$3.47M 0.02% 232
2025
Q4 		$52.3M Buy
822,885
+61,298
+8% +$3.81M 0.02% 234
2025
Q3 		$41.9M Buy
761,587
+27,907
+4% +$1.15M 0.02% 247
2025
Q2 		$24.2M Sell
733,680
-59,778
-8% -$2.08M 0.01% 295
2025
Q1 		$31.9M Buy
793,458
+176,966
+29% +$8.13M 0.01% 268
2024
Q4 		$29M Buy
616,492
+74,208
+14% +$3.85M 0.01% 291
2024
Q3 		$28.6M Buy
542,284
+7,764
+1% +$433K 0.01% 298
2024
Q2 		$29M Sell
534,520
-4,277
-0.8% -$258K 0.01% 290
2024
Q1 		$37.8M Buy
538,797
+2,751
+0.5% +$213K 0.02% 251
2023
Q4 		$44.8M Buy
+536,046
New +$19.4M 0.02% 233

Other funds holding CYTK

Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
EOJOAM
E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Ken Fisher's CYTK Position: Q2 2026 in Review

Ken Fisher reduced its Cytokinetics (CYTK) stake by 3.2% in Q2 2026, selling an estimated $1.76M and leaving 743,697 shares worth $63.4M. The position accounts for 0.02% of the portfolio, ranked #220.

Ken Fisher first reported a position in CYTK in Q4 2023 and has held it in 11 quarters since. 137 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Ken Fisher held 743,697 shares of Cytokinetics worth $63.4M as of Q2 2026.
  • Ken Fisher sold 24,567 Cytokinetics shares in Q2 2026, an estimated $1.76M.
  • Cytokinetics made up 0.02% of Ken Fisher's portfolio in Q2 2026, its #220 holding.
  • Ken Fisher first reported a position in Cytokinetics in Q4 2023 and has held it in 11 quarters since.
  • 137 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Fisher Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.